Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)

View ORCID ProfileLudovica Griffanti, Johannes C Klein, Konrad Szewczyk-Krolikowski, Ricarda A L Menke, View ORCID ProfileMichal Rolinski, Thomas R Barber, Michael Lawton, Samuel G Evetts, Faye Begeti, Marie Crabbe, Jane Rumbold, Richard Wade-Martins, Michele T. Hu, Clare E Mackay
doi: https://doi.org/10.1101/19005819
Ludovica Griffanti
1Oxford Parkinson’s Disease Centre, Oxford, UK
2Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ludovica Griffanti
Johannes C Klein
1Oxford Parkinson’s Disease Centre, Oxford, UK
2Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konrad Szewczyk-Krolikowski
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricarda A L Menke
2Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Rolinski
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
4Institute of Clinical Neurosciences, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michal Rolinski
Thomas R Barber
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
5Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Human Brain Activity, Department of Psychiatry, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lawton
6Population Health Sciences, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel G Evetts
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faye Begeti
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Crabbe
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Rumbold
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Wade-Martins
1Oxford Parkinson’s Disease Centre, Oxford, UK
7Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele T. Hu
1Oxford Parkinson’s Disease Centre, Oxford, UK
3Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare E Mackay
1Oxford Parkinson’s Disease Centre, Oxford, UK
5Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Human Brain Activity, Department of Psychiatry, University of Oxford, Oxford, UK
8Oxford Health NHS Foundation Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: clare.mackay@ohba.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort magnetic resonance imaging (MRI) sub-study (OPDC-MRI) collects high quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.

Participants Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data is currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the LRRK2 or GBA genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder - RBD).

Findings to date Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’s, and RBD, but not Alzheimer’s, suggesting that the effect is pathology specific. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.

Future plans Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.

Strengths and limitations of this study

  • High quality 3T MRI data in a very well phenotyped and longitudinally followed cohort of Parkinson’s and RBD.

  • All imaging data were acquired on the same MRI scanner, quite unique for a study of this duration. The protocol includes both standard sequences, comparable across other studies, and sequences acquired to investigate study-specific research questions.

  • Clinical longitudinal data are acquired every 18 months and will be used to relate baseline imaging with clinical progression. Information about conversion to Parkinson’s of the at-risk individuals will also be available, providing the ultimate validation of potential biomarkers. MRI follow-up is also ongoing, which will allow longitudinal imaging analyses.

  • Statistical maps of published results and support data relative to the analyses are available to share.

  • OPDC-MRI phenotyping is deep and relatively frequent, however the size of the cohort is not at the level of population-level cohort studies. MRI sequences are high quality, but could not exploit the latest advances in the field in order to maintain continuity.

Competing Interest Statement

MTH reports grants from Parkinson's UK Monument Discovery Award during the conduct of the study; other from Biogen Digital and Roche Prodromal Advisory Boards, outside the submitted work. Other authors have nothing to declare.

Funding Statement

The work was supported by the Monument Trust Discovery Award from Parkinson’s UK (J-1403) and by the Wellcome Centre for Integrative Neuroimaging, the MRC Dementias Platform UK, the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the NIHR Oxford Health BRC (a partnership between Oxford Health NHS Foundation Trust and the University of Oxford). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. JCK acknowledges support from the NIHR Oxford Health Clinical Research Facility. MR received funding support from a NIHR Academic Clinical Lectureship and a NIHR Oxford BRC Doctoral Training Fellowship. TRB received funding support from a Wellcome Trust Doctoral Training Fellowship, and a Biomedical Research Council Career Development Fellowship. FB reports personal fundings from National Institute for Health Research, during the conduct of the study.

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Yes

Data Availability

The data presented in this work will be available through the Dementias Platform UK, where data can be accessed by submitting a study proposal. Statistical maps are available on NeuroVault.org (links in manuscript) and support data related to the analyses are available on ORA Data.

https://portal.dementiasplatform.uk

https://ora.ox.ac.uk/objects/uuid:8200af66-f438-4a7b-ad14-e8b032f0a9e7

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 11, 2019.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)
Ludovica Griffanti, Johannes C Klein, Konrad Szewczyk-Krolikowski, Ricarda A L Menke, Michal Rolinski, Thomas R Barber, Michael Lawton, Samuel G Evetts, Faye Begeti, Marie Crabbe, Jane Rumbold, Richard Wade-Martins, Michele T. Hu, Clare E Mackay
medRxiv 19005819; doi: https://doi.org/10.1101/19005819
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)
Ludovica Griffanti, Johannes C Klein, Konrad Szewczyk-Krolikowski, Ricarda A L Menke, Michal Rolinski, Thomas R Barber, Michael Lawton, Samuel G Evetts, Faye Begeti, Marie Crabbe, Jane Rumbold, Richard Wade-Martins, Michele T. Hu, Clare E Mackay
medRxiv 19005819; doi: https://doi.org/10.1101/19005819

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (451)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5258)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (757)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (698)
  • Health Policy (358)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (163)
  • Infectious Diseases (except HIV/AIDS) (5867)
  • Intensive Care and Critical Care Medicine (361)
  • Medical Education (104)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (764)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (142)
  • Occupational and Environmental Health (231)
  • Oncology (479)
  • Ophthalmology (152)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (862)
  • Public and Global Health (2011)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (285)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)